Abstract

Extracorporeal membrane oxygenation (ECMO) is a technology capable of providing short-term mechanical support to the heart, lungs or both. Over the last decade, the number of centres offering ECMO has grown rapidly. At the same time, the indications for its use have also been broadened. In part, this trend has been supported by advances in circuit design and in cannulation techniques. Despite the widespread adoption of extracorporeal life support techniques, the use of ECMO remains associated with significant morbidity and mortality. A complication witnessed during ECMO is the inflammatory response to extracorporeal circulation. This reaction shares similarities with the systemic inflammatory response syndrome (SIRS) and has been well-documented in relation to cardiopulmonary bypass. The exposure of a patient’s blood to the non-endothelialised surface of the ECMO circuit results in the widespread activation of the innate immune system; if unchecked this may result in inflammation and organ injury. Here, we review the pathophysiology of the inflammatory response to ECMO, highlighting the complex interactions between arms of the innate immune response, the endothelium and coagulation. An understanding of the processes involved may guide the design of therapies and strategies aimed at ameliorating inflammation during ECMO. Likewise, an appreciation of the potentially deleterious inflammatory effects of ECMO may assist those weighing the risks and benefits of therapy.

Highlights

  • Extracorporeal membrane oxygenation (ECMO) is a technology capable of providing short-term mechanical support to the heart, lungs or both

  • The combination of a sustained innate immune response and the pro-inflammatory aspects of coagulation result in “pan-endothelial” injury, with leukocyte activation and the production of pro-inflammatory mediators. This ends in a systemic inflammatory response and endorgan damage. Whilst this process shares a number of similarities with the inflammatory response witnessed during cardiopulmonary bypass (CPB), there are a number of important distinctions

  • This is compounded by the fact that many of the available studies were conducted prior to the introduction of modern innovations in ECMO technology

Read more

Summary

Introduction

Extracorporeal membrane oxygenation (ECMO) is a technology capable of providing short-term mechanical support to the heart, lungs or both. Levels of pro-inflammatory cytokines rise rapidly [13,14,15,16,17,18,19], which, in association with activation of the complement and contact systems [20,21,22,23,24,25], results in leukocyte activation [26,27,28]. It is thought that the AP is the principal means of complement activation during extracorporeal circulation (ECC), occurring as a result of blood contacting the foreign material of the circuit [77].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.